459 related articles for article (PubMed ID: 30449551)
1. Bone turnover: Biology and assessment tools.
Szulc P
Best Pract Res Clin Endocrinol Metab; 2018 Oct; 32(5):725-738. PubMed ID: 30449551
[TBL] [Abstract][Full Text] [Related]
2. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.
Szulc P; Naylor K; Hoyle NR; Eastell R; Leary ET;
Osteoporos Int; 2017 Sep; 28(9):2541-2556. PubMed ID: 28631236
[TBL] [Abstract][Full Text] [Related]
3. [Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability].
Szulc P; Naylor K; Pickering ME; Hoyle N; Eastell R; Leary E
Ann Biol Clin (Paris); 2018 Aug; 76(4):373-391. PubMed ID: 30078776
[TBL] [Abstract][Full Text] [Related]
4. Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study.
Bønløkke SE; Rand MS; Haddock B; Arup S; Smith CD; Jensen JEB; Schwarz P; Hovind P; Oturai PS; Jensen LT; Møller S; Eiken P; Rubin KH; Hitz MF; Abrahamsen B; Jørgensen NR
Osteoporos Int; 2022 Oct; 33(10):2155-2164. PubMed ID: 35729342
[TBL] [Abstract][Full Text] [Related]
5. [Significance of Bone Turnover Marker Measurement in the Treatment of Osteoporosis].
Miura M; Satoh Y
Yakugaku Zasshi; 2019; 139(1):27-33. PubMed ID: 30606924
[TBL] [Abstract][Full Text] [Related]
6. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.
Vasikaran S; Eastell R; Bruyère O; Foldes AJ; Garnero P; Griesmacher A; McClung M; Morris HA; Silverman S; Trenti T; Wahl DA; Cooper C; Kanis JA;
Osteoporos Int; 2011 Feb; 22(2):391-420. PubMed ID: 21184054
[TBL] [Abstract][Full Text] [Related]
7. Use of bone turnover markers in postmenopausal osteoporosis.
Eastell R; Szulc P
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):908-923. PubMed ID: 28689768
[TBL] [Abstract][Full Text] [Related]
8. The Utility of Biomarkers in Osteoporosis Management.
Garnero P
Mol Diagn Ther; 2017 Aug; 21(4):401-418. PubMed ID: 28271451
[TBL] [Abstract][Full Text] [Related]
9. Biochemical bone turnover markers in hormonal disorders in adults: a narrative review.
Szulc P
J Endocrinol Invest; 2020 Oct; 43(10):1409-1427. PubMed ID: 32335857
[TBL] [Abstract][Full Text] [Related]
10. Bone turnover markers are associated with higher cortical porosity, thinner cortices, and larger size of the proximal femur and non-vertebral fractures.
Shigdel R; Osima M; Ahmed LA; Joakimsen RM; Eriksen EF; Zebaze R; Bjørnerem Å
Bone; 2015 Dec; 81():1-6. PubMed ID: 26112819
[TBL] [Abstract][Full Text] [Related]
11. [The role of bone metabolic markers in qualification for treatment of osteoporosis. Results of POMOST study].
Przedlacki J; Bartoszewicz Z; Ksiezopolska-Orłowska K; Kondracka A; Grodzki A; Bartuszek T; Bartuszek D; Swirski A; Loth E; Musiał J; Luczak E; Teter P; Lasiewicki A; Walkiewicz A; Drozdowska-Rusinowicz I
Endokrynol Pol; 2009; 60(1):25-32. PubMed ID: 19224502
[TBL] [Abstract][Full Text] [Related]
12. National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges.
Bauer D; Krege J; Lane N; Leary E; Libanati C; Miller P; Myers G; Silverman S; Vesper HW; Lee D; Payette M; Randall S
Osteoporos Int; 2012 Oct; 23(10):2425-33. PubMed ID: 22797491
[TBL] [Abstract][Full Text] [Related]
13. Reference intervals of β-C-terminal telopeptide of type I collagen, procollagen type I N-terminal propeptide and osteocalcin for very elderly Chinese men.
Shou Z; Jin X; Bian P; Li X; Chen J
Geriatr Gerontol Int; 2017 May; 17(5):773-778. PubMed ID: 27137883
[TBL] [Abstract][Full Text] [Related]
14. [The role of biochemical markers of bone turnover in the diagnosis of osteoporosis and predicting fracture risk].
Mohamed Y; Haifa H; Datel O; Fadoua HN; Smeh BH; Mahbouba J; Saoussen Z; Bejia I; Mongi T; Mohamed FN; Naceur B
Tunis Med; 2014 May; 92(5):304-10. PubMed ID: 25504382
[TBL] [Abstract][Full Text] [Related]
15. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression.
Bauer DC; Black DM; Bouxsein ML; Lui LY; Cauley JA; de Papp AE; Grauer A; Khosla S; McCulloch CE; Eastell R;
J Bone Miner Res; 2018 Apr; 33(4):634-642. PubMed ID: 29318649
[TBL] [Abstract][Full Text] [Related]
16. [Modern diagnostics of osteoporosis based on the use of biochemical markers of bone turnover].
Drweska-Matelska N; Wolski H; Seremak-Mrozikiewicz A; Majchrzycki M; Kujawski R; Czerny B
Ginekol Pol; 2014 Nov; 85(11):852-9. PubMed ID: 25675804
[TBL] [Abstract][Full Text] [Related]
17. Reference intervals for serum concentrations of three bone turnover markers for men and women.
Michelsen J; Wallaschofski H; Friedrich N; Spielhagen C; Rettig R; Ittermann T; Nauck M; Hannemann A
Bone; 2013 Dec; 57(2):399-404. PubMed ID: 24076251
[TBL] [Abstract][Full Text] [Related]
18. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring.
Garnero P
Mol Diagn Ther; 2008; 12(3):157-70. PubMed ID: 18510379
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
